Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
salmon calcitonin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Oral salmon calcitonin | DRUG | - |
Inclusion Criteria: * Healthy postmenopausal women Exclusion Criteria: * Previous treatment with other osteoporosis medication Other protocol-defined inclusion/exclusion criteria may apply.
Salmon calcitonin is being studied for use in postmenopausal osteoporosis. It is an investigational small molecule in Phase 1 clinical development, evaluated in healthy postmenopausal women to understand its pharmacokinetics and pharmacodynamics. The drug is not approved and remains in clinical testing.
Salmon calcitonin is being developed by Novartis AG, traded on the New York Stock Exchange under the ticker NVS. The company is conducting clinical research on this investigational drug for postmenopausal osteoporosis.
Salmon calcitonin is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied for postmenopausal osteoporosis. The Phase 1 trial has been completed.
Salmon calcitonin has one completed Phase 1 trial, NCT00411125, titled 'Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women.' The trial enrolled 86 female participants aged 40 years and older in Denmark.
The Phase 1 trial of salmon calcitonin was randomized and double-blind, but it had an uncontrolled design, meaning there was no control group. The study was completed and enrolled 86 postmenopausal women.